ArticleFrontiers in oncology2026
Second primary mediastinal grey-zone lymphoma following treatment for classical Hodgkin lymphoma: a rare case report.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gray-zone lymphoma (GZL) is a rare and biologically distinctive B-cell lymphoma that exhibits overlapping clinical and pathological features between classical Hodgkin lymphoma (cHL) and mediastinal large B-cell lymphoma (PMBL). Mediastinal Gray-zone lymphoma (MGZL) occurring as a second primary malignancy following treatment for cHL is exceedingly rare, and both its pathogenesis and optimal clinical management remain poorly characterized. Case presentation: A 22-year-old woman diagnosed with cHL in 2020 achieved complete remission after ABVD chemotherapy. Five years later, a new mediastinal mass was identified during routine follow-up. Excisional biopsy via video-assisted thoracoscopic surgery (VATS), together with comprehensive immunohistochemical and molecular analyses, confirmed a diagnosis of secondary MGZL. The patient subsequently underwent salvage chemotherapy followed by autologous stem-cell transplantation, achieving clinical remission. Conclusion: In long-term survivors of cHL, the emergence of a new mediastinal mass necessitates repeat biopsy and precise pathological reassessment rather than presumption of relapse. Second primary lymphomas, such as MGZL, require individualized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.